Detalhe da pesquisa
1.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Eur Heart J
; 43(31): 2958-2967, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427295
2.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 380(4): 347-357, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415602
3.
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Circulation
; 142(8): 734-747, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795086
4.
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Diabetes Obes Metab
; 23(4): 1020-1029, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368855
5.
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Diabetes Obes Metab
; 23(1): 29-38, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32844557
6.
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Circulation
; 139(22): 2516-2527, 2019 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30882239
7.
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Diabetes Obes Metab
; 22(7): 1122-1131, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32090404
8.
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Diabetes Obes Metab
; 22(8): 1357-1368, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239659
9.
DECLARE-TIMI 58: Participants' baseline characteristics.
Diabetes Obes Metab
; 20(5): 1102-1110, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29322605
10.
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Diabetes Care
; 46(1): 156-164, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399721
11.
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Lancet Diabetes Endocrinol
; 11(4): 233-241, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878239
12.
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
JAMA Cardiol
; 7(9): 914-923, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857296
13.
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58.
Diabetes Care
; 45(4): 938-946, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015847
14.
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Diabetes Care
; 45(10): 2350-2359, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35997319
15.
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Diabetes Care
; 44(5): 1159-1167, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653824
16.
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Diabetes Care
; 44(8): 1805-1815, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34233928
17.
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Diabetes Care
; 43(2): 468-475, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843945
18.
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Lancet Diabetes Endocrinol
; 7(8): 606-617, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31196815